E.V. BOBYKIN, S.A. KOROTKIKH

Ural State Medical University, 3 Repin Str., Yekaterinburg, Russian Federation, 620028

 Bobykin E.V. ― Cand. Med. Sc., Associate Professor of the Department of Ophthalmology, tel. +7-912-240-03-63, e-mail: oculist.ev@gmail.com

Korotkikh S.A. ― D. Med. Sc., Professor, Head of the Department of Ophthalmology, tel. (343) 214-86-67, e-mail: med@usma.ru

Early results of the switching from ranibizumab to aflibercept in 23 patients with neovascular age-related macular degeneration are presented. The high clinical efficacy and safety of ranibizumab and aflibercept are shown by the statistically significant (p<0.05) improvement in visual acuity and macular anatomy. The authors have statistically confirmed the longer duration of inhibition of choroidal neovascularization (aflibercept ― 2.91±0.17 months, ranibizumab ― 2.65±0.14 months, p<0.05), the more pronounced decrease of the central thickness of the retina (up to 246.9±12.5 μm and 288.7±18.0 μm, respectively, p<0.05) and the volume of the macula (up to 6.74±0.15 mm³ and 7.14±0.19 mm³, respectively, p<0.05) 4 weeks after intravitreal introduction of aflibercept, which demonstrates the possible benefits of the antiangiogenic drugs changing.

Key words: neovascular («wet») age-related macular degeneration, ranibizumab, aflibercept, switching.

REFERENCES

1. Rofagha S., Bhisitkul R.B., Boyer D.S., et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology, 2013, no. 120, pp. 2292-2299.
2. Jacob J., Brié H., Leys A., et al. Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. Int. J. Ophthalmol, 2017, vol. 10, no. 1, pp. 81-90. DOI: 10.18240/ijo.2017.01.14
3. Korotkikh S.A., Bobykin E.V., Nazarova N.S., Melekhina E.E. Anti-angiogenic therapy of neovascular diseases of the macular region (long-term results). Vestnik oftal’mologii, 2016, vol. 132, no. 1, pp. 76-84 (in Russ.). DOI: 10.17116/oftalma2016132176-84.
4. Seguin-Greenstein S., Lightman S., Tomkins-Netzer O. A meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with aflibercept. J. Ophthalmol, 2016, 2016:4095852, 8 p. http://dx.doi.org/10.1155/2016/4095852.
5. Spooner K., Hong T., Wijeyakumar W., et al. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clinical Ophthalmology, 2017, no. 11, pp. 161-177.
6. He L., Silva R.A., Moshfeghi D.M. et al. Aflibercept for the treatment of retinal pigment epithelial detachments. Retina, 2016, vol. 36, no. 3, pp. 492-498.
7. Holz F.G., Tadayoni R., Beatty S., et al. Multi-Country Real-Life Experience of Anti-Vascular Endothelial Growth Factor Therapy for Wet Age-Related Macular Degeneration. Br. J. Ophthalmol, 2014, vol. 99, no. 2, pp. 220-226. DOI: 10.1136/bjophthalmol-2014-305327.
8. Instruktsiya po meditsinskomu primeneniyu preparata “Lutsentis”. Registratsionnyy nomer: LSR-004567/08-020310 [Instructions for the medical use of the drug «Lucentis». Registration number: LSR-004567 / 08-020310].
9. Instruktsiya po meditsinskomu primeneniyu preparata «Eylea». Registratsionnyy nomer: LP-003544-200117 [Instructions for the medical use of the drug «Eilea». Registration number: LP-003544-200117].
10. Bobykin E.V. Sposob intravitreal’nogo vvedeniya lekarstvennykh sredstv v oftal’mologii. Patent na izobretenie RF no. 2581219 [The method of intravitreal administration of drugs in ophthalmology. Patent for invention of the Russian Federation No. 2581219]. Byull. no.11 ot 11.03.2016.